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Methods
A total of 1351 aborigines from the community (511 cases and 840 controls) and 511 Han people from hospital (104 cases and 407 controls) were recruited. SNPs in potentially functional regions of the 38 genes within 4q25 were identified and genotypes determined by direct sequencing. Quantitation of blood ALPK1 mRNA expression levels and luciferase assay of gout-associated rs231253 pGL3-SNP constructs cotransfected with hsa-miR-519e were examined.
Results
We found that ALPK1 gene was the most determinant of gout. Three SNPs of rs11726117 M861T [C], rs231247 [G] and rs231253 [G] were most associated with gout risk [odd ratios (OR) 51.44, P 4 3.78 Â 10 À6 ) in aborigines. A replication set using Han people had risk at rs11726117 and rs231247 (OR 51.72, P 4 4.08 Â 10 À3 ). From pooled analysis (Breslow-Day test, P40.33) assuming an additive model, each increasing copy of the risk allele of rs11726117 [C] , rs231247 [G] and rs231253 [G] showed significantly elevated OR for gout 51.42 (P 5 1.53 Â 10 À6 ). Consistently, the composite homozygous of linked 3 SNPs (versus wild-type, OR ¼ 1.83, P ¼ 8.21 Â 10 À4 ) had strong associations with ALPK1 mRNA expression. Luciferase showed reduced hybridization between hsa-miR-519e and construct carrying gout-associated rs231253 [G] than the wild-type [C] (P ¼ 6.19 Â 10 À4 ).
Conclusions Our study found that a newly identified ALPK1 gene can effectively interfere with microRNA target recognition and modulates the
Introduction
Gout is characterized by monosodium urate (MSU) deposits in the soft tissues of hyperuricaemic patients whose symptoms include recurrent flares of acute gout arthritis, tophaceous deposits of MSU crystals in joints and other tissues, chronic arthropathy, uric acid urolithiasis and renal impairment. 1, 2 Gout patients experience very painful attacks due to the precipitation of MSU crystals in joints, along the Achilles tendon and the first metatarsophalangeal joint, as well as the triggering of inflammatory cytokines, chemokines, proteases and oxidants that lead to damage such as chronic synovitis, cartilage loss and bone erosion. [1] [2] [3] Hyperuricaemia is present in almost all gout patients, however only a minority (20%) of hyperuricaemic individuals experience gout symptoms. 4 Tophus is a severe form of crystal arthropathy that can occur anywhere in the body. Without treatment, tophi occur in 30% of patients within 5 years of onset of gout, 3 whereas others may continue to have flares of acute arthritis without the tophus occurrence. Therefore, studying a possible role for these familial hyperuricaemia-and goutcausing genes in common gout is justified. 5 For the past two decades, public health researches have identified the Taiwanese aboriginals as having a high gout prevalence of 12% 6, 7 especially male aboriginals, with as high as 64% 8 of gout cases exhibiting familial clustering of chronic tophaceous gout. Linguistic and archaeological evidence suggests that the aboriginals were originally one group of expanding Neolithic Setaria farmers who first settled in Taiwan as early as 5500 YBP from the southern coast of China. 9 Their prevalence markedly differs from Taiwanese Han (who immigrated in 300 YBP in large numbers to Taiwan from Guangzhou and Fujian provinces) at 3% 6 and tophi rates that have declined from 34% 10 to 9% 11 of cases during 1948-1984 to 1992-1999 .
Following the genome-wide linkage of aboriginal gout multiplex at marker D4S2623 (at 114cM) on chr4q25 (logarithm of odds [LOD] ¼ 4.29), the Gout Susceptibility1 (GOUT1, ID %138900) was a region hypothesized to influence Taiwanese aboriginal gout. 12 The aborigines are likely to have been isolated in small groups for thousands of years, subjected to higher genetic drift and increased homogeneity. Today, the indigenous population is a minority comprising <3% of entire population of Taiwan. This is an opportunity to study gout-related gene variant differences among ethnicities with special demographic histories, adding to the existing suite of major gout genes discovered.
Methods

Study participants
This study recruited from a community-based Taiwanese aboriginal health cohort study and selected 1351 subjects from 2235 aboriginal highlanders residing in the north central mountains and examined at Township Health Stations since 1994, whom we closely followed up on 511 cases (38.6% had tophi) with chronic gout consistently observed for mean duration of 10 years. 12, 13 The general physicians based at health stations and visiting rheumatology medical specialists carefully diagnosed and followed gout in each aborigine using clinical history, physical exam and blood tests performed 2-4 times annually. Because of limited resources of clinical treatment in the area, only a small proportion (<5%) of aboriginal gout patients were treated with uric acid-lowering agents. Additionally, a replication set, 511 hospitalbased Taiwanese Han (104 gout and 407 controls), of which cases have chronic gout, were consistently observed for mean duration of 8 years.
14 All gout cases were strictly diagnosed by American College of Rheumatology criteria. 15 Among cases, a high proportion had tophaceous gout, 39% aboriginals and 49% Han; these patients must have demonstrated two or more tophi, clearly visible and palpable from arms, legs, ears, or articular cartilage from other sites, and hyperuricaemia (48 mg/dl) when their blood was collected. The controls were 840 healthy aboriginals from the same communities as the aboriginal cases, and 407 gout-free Han from the same hospitals as the Han cases, all ascertained to be unrelated, with no history of gout and not taking hypouricaemic agents for other medical conditions. Trained nurses recorded demographic data by standardized questionnaires. Blood specimens were analyzed using standardized hospital protocols. Hyperuricaemia was defined as uric acid exceeding 7.0 mg/dl in males and 6.0 mg/dl in females. Institutional review boards and ethics committees from Kaohsiung Medical University and National Health Research Institutes approved our study design. All participants gave their written informed consent.
DNA resequencing and SNP genotyping Genomic DNA was extracted from peripheral whole blood by wizard genomic DNA purification kit (QIAGEN-Gentra Puregene Blood Kit) followed standard laboratory protocols. DNA resequencing used Dye Terminator kit (Applied Biosystems) and ABI 3730 mRNA RNA analysis of 62 aborigines (23 gout and 39 controls) was performed using real-time PCR as described previously. 16 Total RNA from human peripheral blood leukocytes was isolated by PAXgene Blood RNA Kit and generated cDNA using TaqMan Reverse Transcription Reagents (Applied Biosystems). The expression experiment of ALPK1 mRNA was performed using pre-designed gene-specific TaqMan probes and primer pairs (Assays-ID: Hs00228473_m1), in triplicate per sample, and a control without template included in each plate. Reference housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified in same plate and equivalent to all samples.
Luciferase assay
The rs231253 allelic differences in promoter activity in the human HEK293 line were confirmed with use of the pGL3-basic vector. Cells were transfected with these reporter constructs and with pRLTK renilla (Promega) luciferase vector as a normalization control. We constructed HEK293 cells (2 Â 10 4 cells per 96-well) were cotransfected with 0.1mg of pGL3-SNP (firefly luciferase), 0.02mg of pGL4.73 (renilla luciferase) (Promega) and 0.1mg of the hsa-miR-519e (Applied Biosystems) plasmid. Cells were lysed 72 h after transfection, in 50 ml of lysis buffer according to the Dual-Glo Luciferase Assay System protocol (Promega) and luciferase activity measured with TopCount NXT luminometer (Packard). Relative luciferase activity of ALPK1 reporter constructs was calculated as the ratio of firefly luciferase activity to renilla luciferase. Reporter assays shown were the average of four independent experiments in triplicates and were analysed by repeated measures analysis.
Statistical analysis
Multipoint analysis was performed using conditionallogistic model implemented in the S.A.G.E. v6.0.1 program for linkage fine-map. We used a one-parameter model and default value that constrained relative risks, 2 ¼ 3.634 1 -2.364, assuming the expression fix for mode of inheritance was a value approximately halfway between a dominant and a recessive model, corresponding to the Whittemore and Tu minmax model mode of inheritance parameter. 17 The likelihood-ratio statistic was computed by multiplying the LOD (logarithm of odds) score by 4.6. Linkage disequilibrium (LD) coefficients (D' and r 2 )
implemented by Haploview v4. 2 18 and PLINK v1.07.
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Genotype frequencies of the controls of ethnic groups regarding investigated SNPs conformed to Hardy-Weinberg equilibrium and were assessed by 2 goodness-of-fit test. The means or proportions for baseline gout risk factors were calculated for cases and controls. Significance of associated risk factors was tested with the 2 statistic for categorical variables and the generalized linear regression models for continuous variables. We analysed the association between SNPs and risk of gout using logistic regression analysis. Additive genetic effects were modelled by defining continuous variables with levels 0, 1 and 2 corresponding to genotypes (i.e. rs11726117 was coded as 0 for TT, 1 for CT and 2 for CC). The Breslow-Day test examined the odds ratio (OR) homogeneity between family-based substructures and population-based aboriginal gout subjects (Breslow-Day test, P ¼ 0.22) were obtained. OR with 95% confidence intervals (CI) was adjusted for age, gender, body mass index, hypertension, alcohol use, hyperuricaemia, total cholesterol, log (triglycerides) and creatinine using a logistic regression model. Pooled analysis was performed by CochranMantel-Haenszel test method using the PLINK v1.07. Case/control traits can be analysed for haplotype associations using PLINK v1.07. We categorized composite genotypes into three categories: risk-homozygous
) and other-type. ALPK1 mRNA expression by composite genotypes was calculated. 
Bioinformatics analysis
Results
Clinical characteristics of study participants are presented in Table 1 . Gout cases had a mean onset age of 40.8 years for aborigines and 45.2 years for Han. Cases showed high urate levels (58.9 mg/dl), 585.5% hyperuricaemia and 538.5% tophaceous gout, and higher mean total cholesterol, triglycerides and creatinine levels (P < 0.01). Gout cases also had significantly increased alcohol intake (P < 0.001). Aboriginal controls showed borderline-high uric acid (57 mg/dl) and triglycerides (199 mg/dl), and 31% were hypertensive. Type 2 diabetes, often comorbid with gout in Caucasians, was insignificant in the aborigines.
Our study scheme is summarized in Figure 1 . A pilot study involved gene-centrically resequenced 666 polymerase-chain-reaction (PCR) amplicons including 38 gene exons, and flanking intron sequences of genes between D4S1647 and D4S2937 region in GOUT1 were typed and 404 SNPs exposed, using 23 unrelated male aboriginal gout case-control pairs to produce the association SNPs (Supplementary Table 1 , available as Supplementary data at IJE online). Although, as for ALPK1, only one SNP is reported as significant (P ¼ 0.041), we cannot rule out the possibility that ALPK1 variants contribute to the gout risk. Increased cohort size had narrowed these SNPs to those belonging to four genes (SCYE1, DKK2, FLJ39370, ALPK1; Supplementary ). SNPs of rs11726117, rs231247 and rs231253 showed homogeneity in associating with gout (Ethnic Breslow-Day test, P40.33). Therefore, pooled analysis of the three SNPs by CochranMantel-Haenszel assuming an additive model was used to test for associations (Table 2) . When individuals were combined into a pooled analysis, each increasing copy of the [C] allele at rs11726117, [G] Figure 1 Region-wide association fine-map of chr4q25 to identify ALPK1. (A) We commenced with a pilot study that gene-centrically resequenced 38 genes (total 404 SNPs) in the 4q25 region using 23 unrelated male aboriginal gout case-control pairs that produced the association SNPs; a confirmatory study was made by adding five dense microsatellite markers into linkage peak at 114cM, then maximal signal migrated to a new peak at 117cM (P ¼ 5.00 Â 10 À7 , LOD ¼ 5.17); raising the cohort size had narrowed down SNPs further to those within four genes (SCYE1, DKK2, FLJ39370 and ALPK1). (B) Using the final 1351 cohort, which consisted 511 gout cases and 840 controls, we isolated nine SNPs which were significantly associated with gout. (C) We replicated independently similar risk in the Han Chinese people. Interestingly, the linked variant at 3'UTR is predicted to be a binding site polymorphism of hsa-miR-519e, suggesting loss of gene regulation among carriers of the affected, a result consistent with luciferase activity in vitro and ALPK1 mRNA expression from blood samples findings allele at rs231247 and [G] allele at rs231253 conferred a significantly elevated OR for gout of 1.51 (P ¼ 2.89Â10 À8 ), 1.52 (P ¼ 2.05Â10 À8 ) and 1.43 (P ¼ 1.53 Â 10 À6 ) after controlling for ethnicity only. The above results were similar even after controlling for ethnicity and hyperuricaemia and other covariates concerning the risk estimate for rs11726117 [ To quantitate the expression differences in genotype carriers of these three SNPs, a real-time PCR of ALPK1 mRNA was performed on peripheral blood leukocytes of 62 aborigines ( Pooled analysis was performed by the Cochran-Mantel-Haenszel test method using the PLINK v1.07. Three SNPs revealed homogeneity in the association with gout (Breslow-Day test, P40.33). OR with 95% CI in parentheses was adjusted for ethnicity, hyperuricaemia and other covariates using a logistic regression model.
ALPK1 VARIANTS ASSOCIATED WITH GOUT
Discussion
Region-wide association fine-map of 4q25 showed the ALPK1 gene to be most associated with gout in Taiwanese aboriginals and Han and closest to newly revised linkage signal at 117cM (LOD ¼ 5.2) in this study. Particularly, three ALPK1 loci of the nonsynonymous rs11726117 M861T [C], synonymous rs231247
[G] and 3'UTR rs231253 [G] were most associated with gout risk. These could cause alterations to the normal physiological function of the ALPK1 of the alpha-kinase family although the functions of ALPK1 are less known. For example, the missense rs11726117 M861T is a threonine substitution located forward of the catalytic domain, and potentially a new phosphorylation site for ALPK1 with preferentially phosphorylate threonine residues. 21, 22 Synonymous rs231247 (R1084R) codes for an amino acid in the alpha catalytic domain, located adjacent to a conserved invariant glutamine, which structurally maintains the alpha-helix C of subdomain III and near a polar residue that binds H 2 O to help orientate the ATP g-phosphate in the binding groove. 21 Uric acid, generated by degradation of purines, is further cleared by degradation to allantoin catalyzed by hepatic uricase, or by excretion largely in the kidneys. Humans, unlike most mammals, lack uricase, and therefore rely on renal excretion as a critical determinant of systemic urate levels. 2 Genome-wide association studies have identified the common polymorphisms in several genes involved in the renal urate transport that are associated with hyperuricaemia and gout, including SLC2A9, SCL22A12, SCL22A11, SLC17A3, ABCG2 and SLC17A1 genes. 24, 25 ABCG2 rs2231142 Q141K has been suggested as a major causative gene variant for gout. 25 However, renal urate transporter gene variants explain only about 5.3% of the total variation of serum urate concentrations in people of Caucasian ancestry. 24, 25 Therefore, many other genes with partial effects and accompanied by high urate levels contribute to formation of MSU crystals and the clinical presentation of acute gout arthritis and chronic tophaceous disease. We found in vitro that the ALPK1 and MSU may synergistically induce ERK1/2 and p38 phosphorylation, then regulate cytokine expressions through the activation of NF-kB pathway. 16 The activated NF-kB complexes are known to translocate into the nucleus and bind to NF-kB DNA binding motifs to trigger transcription of genes that are critical to inflammation, such as cytokines, chemokines and cell adhesion molecules. 1, 26 The ENCODE 'Yale TFBS' track has revealed the entire 10 kb of ALPK1 promoter region to contain several signal peaks of NF-kB transcription factor binding motifs suggested in an overall positive feedback (Supplementary Figure 4 , available as supplementary data at IJE online).
In conclusion, the ethnic replication of association findings between ALPK1 loci and gout has led us to consider ALPK1 as a significant new candidate susceptible gene for gout. Uniquely, a 3'UTR rs231253 variant on ALPK1 has been found to disrupt miRNA gene regulation and contribute to a higher mRNA expression among the patients affected.
